Abstract
Objectives: To evaluate the long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency during the open label extension (weeks 41-113) of the randomized controlled CLUSTER trial. Methods: During a 72-week period, patients received open-label canakinumab 150 or 300 mg, every 4 or 8 weeks. The disease activity was evaluated every 8 weeks using physician global assessment and counting the number of flares. Concentrations of CRP and serum amyloid A protein were measured. The safety was studied by determination and classification of observed adverse events. The safety and efficacy were analysed separately in three subgroups of patients receiving a cumulative dose of less than <35 mg/kg, ≥35 to <70 mg/kg or ≥70 mg/kg. Results: Of the 74 patients who started the CLUSTER study, 66 entered Epoch 4 and 65 completed it. During the 72-week period, 42 (64%) patients experienced no flares, while 13 (20%) had one flare, as compared with a median of 12 flares per year reported at baseline. Low physician global assessment scores were seen at the end of the study for all groups with >90% reporting minimal disease activity or none at all. Median CRP concentrations were consistently equal or lower than 10 mg/l, while median serum amyloid A concentrations remained only slightly above the normal range of 10 mg/l. The study showed no new or unexpected adverse events. Conclusion: Canakinumab proved effective to control disease activity and prevent flares in mevalonate kinase deficiency during the 72-week study period. No new safety concerns were reported.
| Original language | English |
|---|---|
| Pages (from-to) | 2088-2094 |
| Number of pages | 7 |
| Journal | Rheumatology (Oxford, England) |
| Volume | 61 |
| Issue number | 5 |
| Early online date | 23 Sept 2021 |
| DOIs | |
| Publication status | Published - May 2022 |
Keywords
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal/adverse effects
- Double-Blind Method
- Humans
- Hyper IgD syndrome
- Mevalonate Kinase Deficiency/drug therapy
- Serum Amyloid A Protein
- Treatment Outcome
- auto-inflammatory diseases
- canakinumab
- interleukin-1
- mevalonate kinase deficiency
Fingerprint
Dive into the research topics of 'Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver